source
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drug into Phase 3Sling Therapeutics announced a $123 million Series C financing round aimed at moving its oral therapy for thyroid eye disease into a late‑stage trial and eventual market launch. The company has be…
- FDA launches pilot to accelerate early-stage drug trials in the United StatesThe FDA announced a new pilot program called the Expedited Investigational New Drug Pilot as part of Operation Trialblazer. The initiative will pair up to ten qualified research institutions with…